Oral semaglutide, while not yet approved specifically for weight reduction, has shown promising results in improving blood glucose levels among people with type 2 diabetes (T2D). This is particularly notable as its injectable form, sharing similar pharmacological properties, has already received FDA approval for obesity management. A recent real-world longitudinal study by Jothydev’s Diabetes Research Centre has shed light on the potential dual benefits of oral semaglutide for T2D patients. These findings were presented at the 84th Scientific Sessions organized by the American Diabetes Association (ADA) in Orlando, Florida, from June 21-24, 2024.

      The study involved 196 participants, who were divided into three groups based on their weight loss: 0-5%, 5-10%, and over 10%. Statistical analyses were conducted using R version 4.3.1. The results were compelling: participants who achieved a weight reduction of 0-5% saw their HbA1c levels drop by 1.13%. Those with a 5-10% weight loss experienced a 1.3% reduction, and participants who lost more than 10% of their weight saw an impressive 1.98% decrease in HbA1c levels.

      This study highlights that oral semaglutide not only aids in weight loss but also significantly improves blood glucose control, especially in those who achieve substantial weight loss. The dual benefits of oral semaglutide could make it a valuable component of T2D treatment strategies, offering both weight management and glycemic control. Jothydev’s Diabetes Research Centre’s original research underscores the importance of considering oral semaglutide as a versatile tool in diabetes management.